Retrospective analysis shows low-decimal decitabine plus venetoclax improves MRD negativity and survival in AML and high-risk MDS patients, suggesting a new treatment option.
Key Points
This study aims to evaluate the efficacy and safety of low-dose 10-day decitabine combined with venetoclax in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Performed a retrospective analysis of 41 patients with AML and high-risk MDS who were ineligible for intensive chemotherapy.
Patients received decitabine at 6mg/m2 for 10 days and varying doses of venetoclax for up to 21 days.
Analyzed overall survival and event-free survival using Kaplan-Meier analysis.
Achieved composite complete remission rate of 80.5% in 33 out of 41 patients.
63.4% of patients achieved MRD negativity after the first cycle.
Median overall survival was 36.1 months with 12-month OS rate at 68.3%.